{"id":2682,"date":"2019-10-07T15:10:19","date_gmt":"2019-10-07T13:10:19","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=2682"},"modified":"2024-01-16T12:53:02","modified_gmt":"2024-01-16T11:53:02","slug":"models-de-malaltia-en-c-elegans","status":"publish","type":"page","link":"https:\/\/idibell.cat\/recerca\/area-de-medicina-translacional\/programa-de-gens-malaltia-i-terapia\/models-de-malaltia-en-c-elegans\/","title":{"rendered":"Models de malaltia en C.elegans"},"content":{"rendered":"\n

\n\t\tModels de malaltia en C.elegans\n\t<\/h1>\n

\n\t\tResum\n\t<\/h3>\n\t

Utilitzem l’organisme model Caernorhabditis elegans per modelar malalties humanes. El nostre grup ha investigat gens involucrats en el processament d’ARN que estan alterats en malalties rares o c\u00e0ncer. Gr\u00e0cies a les tecnologies CRISPR, estem avan\u00e7ant cap a la medicina personalitzada en imitar mutacions humanes en C. elegans<\/em>. A m\u00e9s, estem aprofitant la viabilitat de C. elegans<\/em> per a l’edici\u00f3 gen\u00f2mica CRISPR per desenvolupar metodologies m\u00e9s eficients i vers\u00e0tils per a editar el loci gen\u00e8tic.<\/p>\n

34<\/h2>\n

Publicacions<\/h2>\n\t\t\t\t\"Modeling-human-diseases-in-C-elegans2\"\n\t\t\t\t\tL\u00ednies estrat\u00e8giques<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tProcessament d’ARN i malaltia
\nModelatge de c\u00e0ncer
\nEdici\u00f3 gen\u00f2mica CRISPR\n\t\t\t\t\t
Publicacions seleccionades<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

Vicencio J, S\u00e1nchez Bola\u00f1os C, Moreno S\u00e1nchez I, Brena D, Vejnar CE, Kukhtar D, Ruiz L\u00f3pez M, Cots Ponjoan M, Rubio A, Melero NR, Crespo Cuadrado J, Carolis C, P\u00e9rez Pulido AJ, Gir\u00e1ldez AJ, Kleinstiver BP, Cer\u00f3n J, Moreno Mateos MA. Genome editing in animals with minimal PAM CRISPR-Cas9 enzymes.<\/strong> Nat. Commun. 2022;13(1):2601-2601. doi:10.1038\/s41467-022-30228-4.<\/p>\n

Mart\u00ednez Fern\u00e1ndez C, Bergamino M, Schiavi A, Brena D, Ventura N, Honnen S, Villanueva A, Nadal E, Cer\u00f3n J. Insights into cisplatin-induced neurotoxicity and mitochondrial dysfunction in Caenorhabditis elegans.<\/strong> Dis. Model. Mech. 2022;15(3):doi:10.1242\/dmm.049161.<\/p>\n

Jungtrakoon Thamtarana P, Marucci A, Pannone L, Bonnefond A, Pezzilli S, Biagini T, Buranasupkajorn P, Hastings T, Mendonca C, Marselli L, Di Paola R, Abubakar Z, Mercuri L, Alberico F, Flex E, Cer\u00f2n J, Porta Riva M, Ludovico O, Carella M, Martinelli S, Marchetti P, Mazza T, Froguel P, Trischitta V, Doria A, Prudente S. Gain of function of Malate Dehydrogenase 2 (MDH2) and familial hyperglycemia.<\/strong> J. Clin. Endocrinol. Metab. 2022;107(3):668-684. doi:10.1210\/clinem\/dgab790.<\/p>\n

Saura Esteller J, Sanchez Vera I, Nunez Vazquez S, Jabalquinto Carrasco J, Cosialls AM, Mendive Tapia L, Kukhtar D, Martinez Bueno MD, Lavilla R, Ceron J, Artal Sanz M, Pons G, Iglesias Serret D, Gil J. Fluorizoline-induced apoptosis requires prohibitins in nematodes and human cells.<\/strong> Apoptosis. 2021;26(1-2):83-95. doi:10.1007\/s10495-020-01651-z.<\/p>\n

Vicencio J, Ceron J. A Living Organism in your CRISPR Toolbox: Caenorhabditis elegans Is a Rapid and Efficient Model for Developing CRISPR-Cas Technologies.<\/strong> CRISPR J. 2021;4(1):32-42. doi:10.1089\/crispr.2020.0103. I<\/p>\n\t\t\t\t\tProjectes seleccionats<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

MCI21008. DEVELOPMENT OF CRISPR-CAS TECHNOLOGIES IN C. elegans TO INVESTIGATE HUMAN PATHOGENIC MUTATIONS AND OTHER GENE VARIANTS, AND TO CREATE RARE DISEASE MODELS<\/strong>. Ministerio de Ciencia e Innovaci\u00f3n. Budget: 139150. 2021-2024. PI: Cer\u00f3n Madrigal, Juli\u00e1n.<\/p>\n

20PSJ012. Towards the first tumor in the genetic model Caenorhabditis elegans. Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer (AECC).<\/strong> Budget: 20000. 2020-2022. PI: Cer\u00f3n Madrigal, Juli\u00e1n.<\/p>\n

PUB22027. INVESTIGO 2022<\/strong> – CERON MADRIGAL, JULIAN. SERVICIO PUBLICO DE EMPLEO ESTATAL SEPE. Budget: 66217,68. 2022-2024. PI: Cer\u00f3n Madrigal, Juli\u00e1n.<\/p>\n\t\t\t\t\"Juli\u00e1n-Cer\u00f3n22\"\n

\n\t\tCer\u00f3n Madrigal, Juli\u00e1n\n\t<\/h4>\n

\n\t\t\n\t\tjceron@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tInvestigadors principals\n\t<\/h2>\n\t\t\t\t\"Juli\u00e1n-Cer\u00f3n22\"\n

\n\t\tCer\u00f3n Madrigal, Juli\u00e1n\n\t<\/h4>\n

\n\t\t\n\t\tjceron@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tENLLA\u00c7OS RELACIONATS\n\t<\/h4>\n

\n\t\t\n\t\tCeronlab\n\t\t<\/a>\n\t<\/h4>\n

\n\t\t\n\t\t@CeronLab\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tEquip\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tCaps de grup\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es postdoctorals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es predoctorals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tSuport cient\u00edfic\t\t\t\t<\/a>\n\t\t\t\t\t\tCaps de grup\n\t\t\t\t\t\t\t\t\t\t\t